CTRI/2019/04/018634已完成4 期
AN EXTENSION OF BBIL/TCV/IV-3/2015 PHASE 4 CLINICAL TRIAL OF TYPBAR TCV®WITH COMPARATOR TYPHIM Vi®: TO DETERMINE THE LEVEL OF ANTI-SALMONELLA TYPHI VI POLYSACCHARIDE IGG ANTIBODIES AT THE END OF APPROXIMATELY 2 YEARS 6 MONTHS AND FOLLOW UP OF A BOOSTER DOSE OF TYPBAR TCV® DOSE IN THOSE WHO HAVE LOWER LEVEL OF ANTIBODIES (BELOW CORRELATE OF PROTECTION) IN HEALTHY PRIMED AND BOOSTER DOSE RECEIVED CHILDREN
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 340
- 试验地点
- 6
- 主要终点
- To determine the long term persistence of immune response of Typbar TCV
研究概览
简要总结
An extension of BBIL/TCV/IV-3/2015phase 4, randomized, multicentric study toevaluate the immunogenicity and safety of booster dose of typhoid Vi capsular polysaccharide-tetanustoxoid protein conjugate vaccine (Typbar TCV®) administered in healthychildren primed with Typhim Vi® and Typbar TCV®.
Prior to administration of booster dose of Typbar TCV®, allthe primed and boostered subjects will be evaluated for anti-salmonellaVi-polysaccharide IgG. Only those subjects found not to be having the protectivelevel of antibody titer(≤2µg/mLas measured by Shousun C. Szu et al method) will be given a booster dose andwill be assessed for boosting effect of Typbar TCV® by measuring theimmunogenicity after a period of 28 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 4.50 Year(s) 至 17.50 Year(s)（—）
- 性别
- All
入选标准
- •1.Healthy primed children who participated in BBIL/TCV/IV-3/2015 phase 4 clinical trial (Initiated: January 2016) 2.For minor subjects whose parent or guardian is able to understand planned study procedures comprehend and will comply with the requirements of the protocol procedures 3.Written informed consent obtained from subjects parent or guardian (if minor) prior to performance of any study specific procedure 4.Generally healthy subjects without acute or chronic, clinically significant pulmonary cardiovascular hepatic or renal functional abnormality as determined by physical examination.
排除标准
- •1.Primed and boostered subjects whose anti-salmonella Vi-polysaccharide IgGtiter are found to be >2µg/mL.
- •2.Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines or vaccines as per UIP schedule during the study period.
- •3.Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product for typhoid).
- •4.Administration of long-acting immune-modifying drugs (e.g. infliximab, rituximab) at any time during the study period.
- •5.Any confirmed or suspected immunosuppressive or immune-deficient condition, based on medical history and physical examination (e.g. Severe Combined Immunodeficiency Disease).
- •6.Subject with history of hypersensitivity to the vaccine or any of its composition or a present or past history of allergic reactions 7.Subjects suffering from acute or chronic infections or any other serious liver, renal, cardiac, respiratory or metabolic disease 8.Subjects with uncontrolled epilepsy or other progressive diseases of nervous system 9.Subjects unwilling to comply with the study procedures 10.Infection with Human Immunodeficiency Virus (HIV) regardless of clinical stage of immunodeficiency or current autoimmune disease.
- •11.Have signs or symptoms that could confound or confuse assessment of study vaccine reactogenicity.
结局指标
主要结局
To determine the long term persistence of immune response of Typbar TCV
时间窗: day -60 to -1 | day 0 | day 28
次要结局
- •Proportion of participants with local and systemic adverse events(•Proportion of participants with Serious Adverse Events)
研究者
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
4 期
Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 VaccineCOVID-19NCT05329038Sinovac Life Sciences Co., Ltd.180
招募中
4 期
A clinical study to assess the long-term immune response after primary vaccination and immune response after re-vaccination with typhoid conjugate vaccineCTRI/2019/07/019996Cadila Healthcare Ltd236
已完成
4 期
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)Encephalitis, Tick-borneNCT00163540Pfizer
已完成
3 期
Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of AgeSARS-CoV-2 InfectionCOVID-19NCT05310084BioNTech SE1,134
已完成
3 期
Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)Pneumococcal InfectionsNCT04384107Merck Sharp & Dohme LLC694